| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/15/2007 | US20070036849 Use of phospholipid arachidonic acids for increasing muscle mass in humans |
| 02/15/2007 | US20070036848 Estrogen compositions and therapeutic methods of use thereof |
| 02/15/2007 | US20070036846 Wound dressing and method of manufacture thereof |
| 02/15/2007 | US20070036841 Method of enhancing an ornithine-urea cycle in ruminant gut tissues to detoxify ammonia and increase local urea recycling to the rumen for microbial protein synthesis |
| 02/15/2007 | US20070036840 Phosphorylated glucomannan polysaccharides containing 1-6 and 1-2 linkages increase weight gain in swine |
| 02/15/2007 | US20070036839 Phosphorylated glucomannane polysaccharides containing 1-6 and 1-2 linkages increase weight gain in poultry |
| 02/15/2007 | US20070036838 Methods and compositions for soothing oral and nasal tissues |
| 02/15/2007 | US20070036836 Amino acid supplementation for a healthy microbiota ecosystem |
| 02/15/2007 | US20070036831 Nanoemulsion compositions having anti-inflammatory activity |
| 02/15/2007 | US20070036828 Group b streptococcus vaccine |
| 02/15/2007 | US20070036821 Seaweed extract composition for retardation of cardiovascular disorders and preservation of healthy cardiovascular function |
| 02/15/2007 | US20070036813 Expression vector comprising nucleotide sequences coding endothelial growth factor protein for use in prevention and treatment of cell proliferative and eye disorders |
| 02/15/2007 | US20070036809 Tolerance-induced targeted antibody production |
| 02/15/2007 | US20070036807 freezing dried biochemical conjugated immunomodulator comprising immunostimulatory polynucleotide sequence and plant Ragweed allergen; genetic vaccines |
| 02/15/2007 | US20070036790 Treatment with anti-vegf antibodies |
| 02/15/2007 | US20070036768 Systems and methods for treating patients with processed lipoaspirate cells |
| 02/15/2007 | US20070036755 Treatment with anti-vegf antibodies |
| 02/15/2007 | US20070036754 Treatment with anti-vegf antibodies |
| 02/15/2007 | US20070036753 Treatment with anti-vegf antibodies |
| 02/15/2007 | US20070036748 Combination therapies for cancer |
| 02/15/2007 | US20070036745 Polymeric materials, their preparation and use |
| 02/15/2007 | US20070036743 Antimicrobial polymers |
| 02/15/2007 | US20070036732 Stable topiramate formulations |
| 02/15/2007 | US20070036731 Topical Delivery with a Carrier Fluid |
| 02/15/2007 | US20070036730 Cellulose derivatives |
| 02/15/2007 | US20070036726 Diagnosing the health of the eye by staining the tear film with a staining dye, everting the upper eyelid, and observing the lid wiper portion of the everted eyelid for infiltration of the staining dye into the cells thereof; dry eye diagnosis |
| 02/15/2007 | US20070036717 Chemoradiotherapy with TS-1/camptothecins |
| 02/15/2007 | US20070036714 Porphyrin derivatives, methods for obtaining same, and use thereof in radioimmunotherapy |
| 02/15/2007 | DE112005000708T5 Ionen bindende Zusammensetzung Ion scavenging composition |
| 02/15/2007 | DE10242062B4 Hydrierte kondensierte Palatinose, Verfahren zu deren Herstellung und deren Verwendung Hydrogenated condensed palatinose, processes for their preparation and their use |
| 02/15/2007 | DE102006037632A1 Microbiological mixture, useful for applying on a skin surface to treat e.g. fungus and bacteria infections, comprises piezoelectric nano-structures, reductive/oxidative microorganisms, conjugated biopolymer and/or 5-aminolevulinic acid |
| 02/15/2007 | DE102005038632A1 New acylated tryptophan derivatives, useful for controlling male and female fertility, are antagonists of follicle-stimulating hormone receptor |
| 02/15/2007 | DE102005038347A1 Herstellung einer Oxaliplatin-Lösung und Behälter sowie Behälter-Set mit der Lösung Producing an oxaliplatin solution and container and container set with the solution |
| 02/15/2007 | DE102005038141A1 Substituierte 8-(3-Aminopropyl)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-on-Derivate Substituted 8- (3-aminopropyl) -1-phenyl-1,3,8-triaza-spiro [4.5] decan-4-one derivatives |
| 02/15/2007 | DE102005037733A1 Adeninderivate Adenine derivatives |
| 02/15/2007 | DE102005037653A1 Stabile, flüssige Formulierung von Paracetamol A stable liquid formulation of paracetamol |
| 02/15/2007 | DE102005037499A1 Pyrazolderivate Pyrazole derivatives |
| 02/15/2007 | DE102005035112A1 Neues Verfahren zur Herstellung von Tiotropiumsalzen unter Anwendung von in organischen Lösungsmitteln löslichen N-Methylscopiniumsalzen New process for the preparation of tiotropium salts, using organic solvent-soluble N-Methylscopiniumsalzen |
| 02/15/2007 | DE102005034973A1 Salz von Dimethylaminomethyl-phenyl-cyclohexan und dessen kristalline Formen Salt of dimethylaminomethyl-phenyl-cyclohexane, and its crystalline forms |
| 02/15/2007 | DE10141651B4 Transdermales Therapeutisches System (TTS) mit dem Wirkstoff Fentanyl und Verfahren zu seiner Herstellung Transdermal therapeutic system (TTS) with the active ingredient fentanyl and process for its preparation |
| 02/15/2007 | CA2659961A1 Targeted protein kinase c inhibitors and uses thereof |
| 02/15/2007 | CA2633565A1 Pharmaceutical compositions of silicon-containing substituted adenosine nucleoside amide analogs |
| 02/15/2007 | CA2626723A1 Xanthine derivatives as selective hm74a agonists |
| 02/15/2007 | CA2626174A1 Formulations and methods for enhancing the transdermal penetration of a drug |
| 02/15/2007 | CA2620960A1 3, nb dihydrotetrabanezine for the treatment of schizophrenia and other psychoses |
| 02/15/2007 | CA2620952A1 3, 11b-cis-dihydrotetrabenazine for the treatment of a proliferative disease or an inflammation |
| 02/15/2007 | CA2619612A1 Drug delivery system for topical administration |
| 02/15/2007 | CA2618977A1 Orally disintegratable tablet |
| 02/15/2007 | CA2618963A1 Xanthine derivatives as selective hm74a agonists |
| 02/15/2007 | CA2618633A1 Adenine derivatives |
| 02/15/2007 | CA2618631A1 Method for producing cercosporamide |
| 02/15/2007 | CA2618622A1 Novel cercosporamide derivative |
| 02/15/2007 | CA2618586A1 Novel substituted 1,2,3-triazolylmethyl-benzothiophene or -indole and their use as leukotriene biosynthesis inhibitors |
| 02/15/2007 | CA2618542A1 Prophylactic/therapeutic agent for cancer |
| 02/15/2007 | CA2618524A1 Pyrazole derivatives having tyrosine kinase activity |
| 02/15/2007 | CA2618486A1 Ep2 receptor agonists |
| 02/15/2007 | CA2618481A1 Compounds for treating alzheimer's disease |
| 02/15/2007 | CA2618474A1 Compounds for treating alzheimer's disease |
| 02/15/2007 | CA2618446A1 Method of obtaining 3,3-diphenylpropylamines |
| 02/15/2007 | CA2618404A1 Block copolymer compositions and uses thereof |
| 02/15/2007 | CA2618370A1 Oxazolopyridine derivatives as sirtuin modulators |
| 02/15/2007 | CA2618368A1 Imidazopyridine derivatives as sirtuin modulating agents |
| 02/15/2007 | CA2618360A1 Benzothiazoles and thiazolopyridines as sirtuin modulators |
| 02/15/2007 | CA2618256A1 Modulation of cell fates and activities by phthalazinediones |
| 02/15/2007 | CA2618255A1 Itraconazole compositions with improved bioavailability |
| 02/15/2007 | CA2618165A1 Imidazopyridine derivatives as cannabinoid receptor ligands |
| 02/15/2007 | CA2618112A1 Pyridone compound |
| 02/15/2007 | CA2618108A1 Composition and method for use in cartilage affecting conditions |
| 02/15/2007 | CA2618103A1 Substituted triazole derivatives as oxytocin antagonists |
| 02/15/2007 | CA2618093A1 Composition and method for use in cartilage affecting conditions |
| 02/15/2007 | CA2618089A1 Bicyclo[2.2.]hept-7-ylamine derivatives and their uses |
| 02/15/2007 | CA2618084A1 Microparticle compositions of the topoisomerase i inhibitor 7-tert-butoxyiminomethylcamptothecin |
| 02/15/2007 | CA2618081A1 Methods and compositions for inhibition of vascular permeability |
| 02/15/2007 | CA2618069A1 Dihydroxyanthraquinones and their use |
| 02/15/2007 | CA2618019A1 Compounds for the treatment of alzheimer's disease |
| 02/15/2007 | CA2618013A1 Beta-secretase inhibitors for use in the treatment of alzheimer's disease |
| 02/15/2007 | CA2617969A1 Therapeutic agent for diabetes |
| 02/15/2007 | CA2617964A1 Azole and thiazole derivatives and their uses |
| 02/15/2007 | CA2617951A1 Novel camptothecin analogues compounds, a method for the preparation thereof and pharmaceutical compositions containing said compounds |
| 02/15/2007 | CA2617934A1 Transdermal drug delivery formulation |
| 02/15/2007 | CA2617898A1 Staurosporine derivatives for treating non-small cell lung cancer |
| 02/15/2007 | CA2617897A1 Method for the treatment of dyspnea comprising combined administration of tiotropium salts and salts of salmeterol |
| 02/15/2007 | CA2617873A1 Formulations for 7-(t-butoxy)iminomethyl camptothecin |
| 02/15/2007 | CA2617805A1 Novel formulations comprising fenofibrate and a statin, and related methods of treatment |
| 02/15/2007 | CA2617788A1 Sphingosine kinase inhibitors and methods of their use |
| 02/15/2007 | CA2617760A1 Pyrimidine compounds as serotonin receptor modulators |
| 02/15/2007 | CA2617741A1 Horehound composition for reducing snoring, package and method |
| 02/15/2007 | CA2617717A1 Use of tiotropium salts in the treatment of severe persistant asthma |
| 02/15/2007 | CA2617703A1 Androgen modulators |
| 02/15/2007 | CA2617557A1 Benzimidazole derivatives as sirtuin modulators |
| 02/15/2007 | CA2617532A1 Imidazo [2,1-b] thiazole derivatives as sirtuin modulating compounds |
| 02/15/2007 | CA2617492A1 Adjuvant chemotherapy for anaplastic gliomas |
| 02/15/2007 | CA2617484A1 Use of lipid conjugates in cystic fibrosis and applications thereof |
| 02/15/2007 | CA2617473A1 Acylguanidine derivative or salt thereof |
| 02/15/2007 | CA2617327A1 Salts of vildagliptin |
| 02/15/2007 | CA2617324A1 Aminoethane sulfonamide orexin receptor antagonists |
| 02/15/2007 | CA2617293A1 7-substituted aza-indazoles, compositions containing same, production method and use thereof |
| 02/15/2007 | CA2617289A1 Process for preparing an angiotensin ii receptor antagonist |
| 02/15/2007 | CA2617280A1 Pharmaceutical form with sustained ph-independent active ingredient release for active ingredients having strong ph-dependent solubility |
| 02/15/2007 | CA2617274A1 Use of hdac inhibitors for the treatment of myeloma |